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Abstract
Submit Date: 27 March 2022
According to WHO Coronavirus (COVID-19) Dashboard, as of 11th February 2022,
Accept Date: 16 July 2022
Available online: 30th Sept. 2022 there have been 404,910,528 confirmed cases of COVID-19, including 5,783,776 deaths.

Coronavirus-2 (SARS-CoV-2) is the causative agent. It is caused by coronavirus-2
Keywords

(SARS-CoV-2), the disease may cause acute respiratory distress syndrome (ARDS), that
increases the susceptibility of co-infections with fungi. Acute invasive fungal sinusitis



COVID-19

(AIFS) is a severe infection mostly affecting immune-compromised patients and carries



invasive fungal

high risk of mortality. COVID-19 patients admitted to the ICU have risk factors for

sinusitis


fungal pathogens



diagnosis



treatment

AIFS, mainly chronic diseases of the respiratory tract, treatment with corticosteroid,
intubation/mechanical ventilation, and cytokine storm. Aspergillus and Mucorales are
the causative fungi of most AIFS cases, but other atypical fungi can be involved
especially among patients receiving azole prophylaxis. Most AIFS cases have symptoms
like fever, nasal congestion, and facial swelling. Diagnosis of AIFS is made by
endoscopy and radiology associated with clinical examination. The gold standard test for
diagnosis of AIFS is histopathology, though pan-fungal PCR plays an important role.
Therapy

of

AIFS

includes

surgery,

antifungal

agents,

and

correction

of

immunosuppression status

Corresponding author: Heba Eldegla Associate professor of Medical Microbiology and Imuunology, Faculty of Medicine
Mansoura University, Egypt. Tel: +201006454655 . Email: heba_degla@mans.edu.eg

Published by Mansoura Medical Journal, 2023

1

Mansoura Medical Journal, Vol. 51 [2023], Iss. 3, Art. 2
Elzar etal.,

140

The pandemic of COVID-19

Introduction
The epidemic of respiratory infection caused by the new
coronavirus SARS-CoV-2 that occurred by the end of

Origin of COVID 19 pandemic

2019 in China and became a global pandemic
associated with large number of deaths. The death rate
varies between different regions, with unclear high rate
in some countries.1 Alongside Acute Respiratory
Distress Syndromes (ARDS) caused by it, Coronavirus
disease

2019

(COVID-19)

patients

are

immunocompromised due to a lowered CD4 T and CD8
T cells.2 This causes several bacterial and fungal

By the end of 2019 in Wuhan, China, many
cases of lower respiratory tract infections were caused
by a new corona virus severe acute respiratory
syndrome coronavirus 2 (SARS-COV-2). The virus is
of zoonotic origin and has high potential transmission
from human to human leading to rapid epidemic in
China and subsequent global pandemic.6

infections that may occur simultaneously with a
preexisting disease (diabetes mellitus, lung disease) or
may suffer a hospital-acquired infection.3 Acute
invasive fungal sinusitis (AIFS) is a lethal infection that
develop in immune-suppressed patients and represent
the most severe form of fungal sinusitis with following
serious morbidity and mortality. It is highly frequent in
individuals with malignancy, uncontrolled diabetes,
AIDS, immunosuppressive, chemotherapeutic drugs
and COVID-19.4,5 This review aims to demonstrate the
possible association between invasive fungal sinusitis

Virology of SARS- COV-2
SARS-CoV-2 is an enveloped β-coronavirus,
with a nearly identical genome of SARS-CoV-1 and bat
coronavirus.7 In the viral envelope, several proteins
project from it including spike (S) glycoprotein,
envelope (E), and membrane (M) proteins (fig 1).
Several mutations have developed in the viral genome
(RNA). SARS-CoV-2 has a higher number and much
more affinity to host receptors than SARS-CoV-1,
suggesting more easy spread.8

and COVID-19 pandemic highlighting the diagnostic
and therapeutic challenges.

Figure 1: Schematic structure of SARS-CoV-2 9
structural proteins such as spike (S), membrane

direct or indirect contact with nasal, conjunctival, or

(M), envelope (E), and nucleocapsid (N) proteins. The

oral mucosa. The epithelium of the oropharynx and

S, M, and E proteins are embedded in the viral

upper airway, the conjunctiva and gastrointestinal tracts

envelope. The N protein interacts with viral RNA.

harbor the target host receptors.10

Transmission of SARS-COV-2

Pathogenesis of COVID-19

Transmission of SARS-COV-2 occurs via

The viral S protein mediates binding to target

infected respiratory droplets, and infection occurs by

host cell receptor (angiotensin-converting enzyme 2)

https://mmj.mans.edu.eg/home/vol51/iss3/2
DOI: 10.21608/mjmu.2022.129792.1092
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which is expressed on multiple human cells followed by

Prognosis of COVID-19

viral entry. The ACE 2/angiotensin has an essential role
in inflammation and tissue injury.

11

Worse outcomes are associated with ARDS,

ACE 2 expression

AKI and myocardial infarction. High inflammatory

was reported to be attenuated in females compared to

biomarkers (CRP, ferritin), lactate dehydrogenase,

12

13

males and was found to be age dependent. The level

hypokalemia, hypophosphatemia and coagulopathy

of inflammatory cytokines is related to the severity of

(elevated D-dimer and PT) are predictors of mortality. 21

COVID-19. Significant decrease in lymphocytes and
natural killer cells count is detected in patients with

Assessment and diagnosis of COVID-19

severe disease. Also, an increase in expression of

Diagnostic Testing by Polymerase Chain Reaction

inhibitory receptor to natural killer cells is associated

and Serology

with attenuation of T lymphocytes.

14

The standard for diagnosis is detection of Viral

Clinical manifestations of COVID-19
The incubation period range from 1–14 days.
15

RNA by polymerase chain reaction (PCR) from

Children and adolescents represent < 2% of cases who

respiratory samples (eg, nasopharynx). False-negative

16

results are related to amount of the specimen, time from

Death is uncommon in this group of age. Symptoms

exposure, and specimen source. Lower respiratory

include low-grade fever, cough and anorexia.17 Clinical

samples are more sensitive than upper respiratory

manifestations of COVID-19 pneumonia in adults

ones.22 Serology based on detection of antiviral

include pyrexia, dry cough, sore throat, headache,

antibodies can also be used.23

are mostly asymptomatic or have mild symptoms.

fatigue, myalgia and difficult breathing.18 Presentation
ranges from mild (81%) to moderate pneumonia (14%),

Laboratory Findings

and critical illness (leading to invasive mechanical

Typical laboratory abnormalities included high

ventilation, multi-organ dysfunction or death). Mortality

serum C-reactive protein (>60% of cases), lactate

rate depends on age, underlying comorbidities and

dehydrogenase (~50-60%), alanine aminotransferase

disease severity, reaching up to 49% in critically ill

(~25%), aspartate aminotransferase (~33%) and low

patients.

19

albumin (~75%).24 The most common hematological
finding was lymphopenia (~83%)

lymphocyte count <1.0 × 10 /L. Modest prolongation of

Complications of COVID-19
Most

complications

cardiopulmonary

systems.

with absolute

9

are

associated

Cardiac

with

prothrombin times (~ >5%), mild thrombocytopenia

complications

(~30%) and elevated D-dimer (43%-60%) were also

include myocarditis, arrhythmia, and ischemia; while

observed.25

the most prevalent pulmonary complications are
bacterial

pneumonia,

pneumothorax,

effusion.

Guillain−Barré

syndrome,

and

pleural

encephalitis,

Imaging
Early

in

the

disease,

chest

computed

polyneuropathy, delirium, psychosis and tinnitus were

tomographic (CT) findings and chest radiograph can be

also observed. Thrombotic problems such as deep‐vein

normal where abnormalities occur in the first 2 weeks.

thrombosis and pulmonary embolism have also been

The chest CT imaging abnormalities were peripheral

described, association with acute kidney injury (AKI)

ground-glass opacities. They are nonspecific, so it is of

and renal failure was also a possibility.20

limited diagnostic value.24

Published by Mansoura Medical Journal, 2023
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Sinusitis caused by fungi may be invasive or

Treatment of COVID-19

not according to the extent of fungal extension into the

Respiratory Support
Supplemental oxygen is needed in more than

sub-mucous layer and the nearby vascular system.29

75% of hospitalized patients. If no response occurred,

The non-invasive form comprises allergic types,

heated high-flow nasal cannula or invasive mechanical

superficial mycosis and sinus mycetoma. Invasive form

ventilation may be required. Patients should be moved

is subdivided into chronic and acute and both occur in

to airborne isolation room and donning personal

immune-compromised

protective equipment should be performed prior to

fungal sinusitis continues over months to years, in

intubation.

26

diabetic

patients

corticosteroids.

Targeting the Virus and the Host Response

30

or

subjects.
patients

Chronic
on

low

invasive
dose

of

While, AIFS progresses rapidly over

Antivirals (remdesivir, favipiravir) were found to

less than one month and occurs in subjects with more

be effective early, antibodies (convalescent plasma,

severe immunocompromisation and associated with

immunoglobulins),

high mortality up to 50–80%.31

anti-inflammatory

drugs

(dexamethasone), targeted immunomodulatory therapies
(tocilizumab, anakinra), anticoagulants (heparin), and

Incidence of AIFS

antifibrotics (tyrosine kinase inhibitors) have been used.

The incidence of AIFS showed a significant

Trials of chloroquine/hydroxychloroquine, compounds

association (P < 0.05) with post-COVID-19 patients

have been tested, but early data have not demonstrated

than in non-COVID-19.32 At least 10% of COVID-19

clear benefit.27

patients in ICU develop Aspergillus co-infection.33

Post COVID invasive opportunistic fungal infections

Risk factors of AIFS

Decreased CD4 T and CD8 T cells counts

One study detected the

with over expressions of cytokines in COVID-19

predisposing

patients make them vulnerable to fungal co-infections.

particularly acute myeloid leukemia, and diabetes

Life threatening invasive fungal infections affects

(Table 1).34 A meta-analysis showed that diabetes was

patients with hematologic malignancy, organ transplant

the most common followed by hematologic malignancy,

recipients,

and

corticosteroid use, renal or liver failure, solid organ

uncontrolled diabetics. Corticosteroid therapy increases

transplantation, acquired immunodeficiency syndrome

secondary fungal infection risk. So it is likely that,

(AIDS),

coronavirus by itself may not raise the risk for fungal

COVID-19 patients in intensive care units (ICU) share

infections, but other factors may have. Also

broad

risk factors for AIFS, particularly chronic respiratory

spectrum antibiotics usage raises the risk of endogenous

diseases, corticosteroid therapy, intubation/mechanical

immune-compromised

patients

fungal infections including candida species.

28

and

ventilation,

factors

for

autoimmune

and

AIFS

most prevalent
were

leukemia,

disease.31 Hospitalized

cytokinic

storm.1

Acute invasive fungal sinusitis in the context of
COVID-19
Definition of acute invasive fungal sinusitis (AIFS)
Table (1): Prevalence of predisposing factors for AIFR 34
Variable
Prevalence in AIFR Group
Acute myeloid leukemia (AML)
42.9% (18/42)
Diabetes
28.6%
Other leukemia (non-AML)
19.0%
Multiple myeloma
7.1%
Solid organ malignancy
7.1%
Solid organ transplant
4.8%
Myelodysplastic syndrome
2.4%
Non-Hodgkin lymphoma
2.4%
None
2.4%

https://mmj.mans.edu.eg/home/vol51/iss3/2
DOI: 10.21608/mjmu.2022.129792.1092

Prevalence in Control Group
38.1% (16/42)
9.5%
21.4%
7.1%
0%
9.5%
7.1%
11.9%
0%

4

Elzar et al.: Invasive Fungal Sinusitis Associated with COVID-19
143

Invasive Fungal Sinusitis Associated with COVID-19

factors share in increasing susceptibility of IFI.37 The

Pathophysiology of AIFS
Fungal spores are numerous in the atmosphere

condition starts in the nose and paranasal sinuses and

and easily cause disease in the nose and paranasal

spread to the orbit which explains bad prognosis. The

sinuses. Inhaled fungi form part of the normal sinonasal

invading fungus destroys the surrounding bone and soft

flora, but in conditions such as antibiotic use for long

tissue by vascular thrombosis and tissue infarction and

duration, bad ventilation and humid environment

may extend to brain.38

associated with immunocompromised patients, make
fungal infection more likely.35 The high aggressive

Causative fungi

nature of the SARS-CoV-2 causing bilateral alveolo-

Many fungal species can cause AIFS, but the

interstitial lesions in the lung make the occurrence of

most commonly involved were Aspergillus, Rhizopus,

invasive fungal infections (IFI) more likely, including

Mucor, and Rhizomucor, figure (1).39,40 Aspergillus

invasive

and

species predominate among hematologic malignancy

Additionally, absolute number of T

patients, whereas mucor predominate among poorly

lymphocytes, CD4+T and CD8+T are markedly lower

controlled diabetes patients. less commonly atypical

in severe cases, together with markedly higher levels of

fungi are involved like Fusarium, and

pulmonary

mucormycosis.

35

aspergillosis

(IPA)

41

interleukin 2 (IL-2), IL-6, IL-10, tumor necrosis factor

species.

(TNF) alpha and other inflammatory markers, all these

demonstrated in table (2). 34

A

C

Alternaria

The frequency of cultured fugal pathogens is

B

D

Fig. (2): Aspergillus species 42
A Colony morphology on specific culture medium. B: Branching septated hyphae on H&E tissue staining
C,D: Lactophenol Cotton Blue staining, showing septate hyphae and swollen vesicle giving rise to phalides from which
chains of conidia arise.

Fig. (3): Rhizopus species 43
A: Colony morphology on specific culture medium;

Published by Mansoura Medical Journal, 2023

B: Zygospores on wet mount
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Fig. (4): Mucor on Lactophenol Cotton Blue staining 44
Broad aseptate hyphae, with extension of columella into sporangium and aggregation of sporangispores
Table 2: Cultured fungal pathogens in patients with AIFR 34
Fungal Species
Aspergillus species
Mucor species
Curvularia species
Fusarium species
Bipolaris species
Alternaria species
Unknown
Clinical Manifestations of AIFS

Frequency
42.9%
23.8%
7.1%
2.4%
2.4%
2.4%
19.0%
cavernous sinus and orbit causes complications

Facial pain and swelling, pyrexia, nasal

including orbital apex syndrome, superior orbital fissure

blockage, and feeling pain in the eye occur in > 50% of

syndrome, or thrombosis of the cavernous sinus.

31

patients. Ocular changes, proptosis, and weaknning of

Intracranial extension leads to change of the mental

the extraocular muscles are less common, but manifest

status or neuropathy of the cranial nerves.44 The

in progressive disease.39 When the disease spreads

frequency of presenting signs and symptoms is

outside the sinuses, it may embrace the orbit, cavernous

demonstrated in table (3). 31

sinus, or intracranial space. Propagation to the
Table 3: Presenting Signs and Symptoms in AIFS 31
Sign or symptom
Swelling of the face
pyrexia
Nasal congestion
Ocular pain
Proptosis
Decreased vision
Nasal discharge
Facial pain
Headache
Cranial nerve palsy
Altered mental status
Palatal necrosis/ulcer

https://mmj.mans.edu.eg/home/vol51/iss3/2
DOI: 10.21608/mjmu.2022.129792.1092

Frequency
64.5%
62.9%
52.2%
50.9%
48.9%
48.9%
48.1%
46.8%
46.3%
41.5%
21.1%
20.8%
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pupil similarity, reactivity, and status of the sclera and

Mortality
It is under recorded how fungal co-infection
during COVID-19 affects mortality. But the impact of
influenza/IPA co-infection is well known with mortality
reaching 23%.

46,47

conjunctiva.45
Nasal Endoscopy
Endoscopic

nasal

examination

provides

In a study by Schauwvlieghe, the 3-

information about health of mucosal surfaces. Pallor or

month mortality rate of influenza is 51% when coupled

decreased sensation suggest early signs of AIFS,

48

with IPA and 28% without it. In France, IFI causes 9.2

whereas necrosis occurs in late stage. When AIFS is

49

localized to paranasal sinuses, the nasal endoscopy may

Mortality is high (50 - 80%) in intracranial or orbital

appear normal; that is why why if nasal endoscope

affection,

examination is negative does not exclude possibility of

to 40% of mortality in patients with co-morbidities.

irreversible

mucormycosis.

immune

suppression,

and

35

AIFS. The radiology completes the diagnosis.45
Radiology

Diagnosis of AIFS
Physical head and neck examination

CT and magnetic resonance imaging (MRI) are
the ultimate popular used techniques. CT provides

Evaluation of nose, mouth (teeth and palate),

information about bone safety around nasal sinuses, orbits,

soft tissue, ophthalmologic, and cranial nerves should

and base of the skull. If there are abrasions of the bone or

be considered.. mucosa of the nose and mouth are

soft tissue extension seen by CT (Fig. 4), suggestion of

examined for pallor or necrosis, the teeth are examined

AIFS remain high.45 Fat stranding, lost fat planes, and

for looseness or increased sensitivity to hot and cold

inflammatory changes outside the sinuses could suggest

items, and the visual exam includes acuity of vision,

spread outside the sinuses (Fig. 5).50

Fig. (5): CT and nasal endoscopy of AIFS 45
a CT detects demineralization of left inferior turbinate (arrow) and soft tissue thickening.
b View of necrotic left inferior turbinate (arrow) by the endoscope.
c View after turbinate resection (arrow).

Fig. (6): Non-contrast axial CT in AIFS 45
Total opacity of right maxillary sinus with demineralization and impairement in the posterior lateral maxillary sinus
wall. Also, loss of fat plane posterior to the maxillary sinus due to inflammation

Published by Mansoura Medical Journal, 2023
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MRI was proposed as the former techniques

(Fig. 6).52 If there is doubt of intracranial or intraorbital

for diagnosis of AIFS. Although, limitations include

extension, both CT and MRI are considered. Also, CT

difficulty, time length and cost.

51

Loss of contrast

enhancement on MRI occurs in ~50% of AIFS patients

chest detect COVID-19 signs or concurrent pulmonary
infection.53

Fig. (7): MRI changes associated with AIFS 45
a Iso-intense lesion within the upper part of the sphenoid sinus.
b Loss of contrast enhancement
stained with hematoxylin and eosin (H&E) (Fig.7). 54,55
Frozen section support operative decision and confirm

Histopathology
Histopathology revealed a clue of angio-

fungal tissue invasion. Gomori methenamine silver

invasion and lumenal thrombosis. Angio-invasion is the

(GMS) stain also confirm fungal presence in tissues.45

gold

whereas 39 were positive on frozen periodic acid-Schiff

standard

for

diagnosis

of

AIFS

and

is

demonstrated filamentous parts on pathology specimens

stain (PASF).28

Fig. (8): Sinus histopathology 54
A, Bone and sinus tissue (400×, H&E): Fungal forms infiltrating arteries (arrow).
B, Sinus tissue (400×, H&E): Area of acute inflammation and fungus infiltrating arterial wall (arrow).

In a review of 271 biopsies evaluated for AIFS, 41 were

causing AIFS leads to false positives results.56 Beta-D-

positive on H&E staining. Of those 41 positive

glucan is another component of most fungal cell walls

specimens, 34 were found positive on frozen H&E

except mucor mycosis and represents another serum

pathology,

marker which is used in diagnosis of invasive

Fungal Markers

Aspergillosis, but with few details on its use in AIFS.57

Measurement of Aspergillus galactomannan

Microbiology techniques

(GM) in the serum can help diagnosis of invasive

Direct microscopic evidence of fungal hyphae

Aspergillosis, but with imperfect sensitivity (< 50%)

using 10% KOH in endoscopic sample is done initially

and specificity. Cross reactivity with other fungi

and

https://mmj.mans.edu.eg/home/vol51/iss3/2
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later

confirmed

by

fungal

culture

and

8
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histopathology if radiology is nonspecific.35 Fungal

considered.64 Treatment of atypical fungal causes of

stains performed on tissue specimens are positive in few

AIFS should be guided by existing expert consensus

Cultures are positive in 50 to 95% of cases.

guidelines.65 Continue treatment until compete clinical

Pan-fungal PCR may elevate the sensitivity to > 70–

and radiologic resolution and until no normal fungal

59

biomarkers, and negative fungal cultures on repeat

cases.

58

80% and decrease the time needed to reach diagnosis.

The diagnosis by PCR lacks antifungal susceptibility

cultures).40

results. The Identification of the species level together

Correction of Immunosuppression

with

antifungal

susceptibility

antifungal therapy.

testing

can

guide

45

stimulating therapies (Granulocyte- colony stimulating
factor

Medical Management
Urgent

Multi-institutional review showed that immune

surgical

debridement,

[G-CSF],

Granulocyte

monocyte-

colony

antifungal

stimulating factor [GM-CSF], granulocyte transfusion,

therapy, and correction of immunosuppression are the

or all of them) ) lead to 70% lowering in one month

pillars of treatment of AIFS. Management requires a

death in AIFS patients.39

multidisciplinary approach of different specialists

Surgical Management

45

according to extent of infection. Additionally medical

First of all, surgeons should decide if the

management for COVID-19 should also be started.

patient needs surgery. Once the decision is made, the

Antifungal Therapy

timing of surgery is also critical. Prompt surgical should

Immediate treatment with antifungal agents

be conducted if there is proof of serious complication

should be started emperically based on clinical

(vision loss) but elective surgery is considered if the

suspicion for AIFS; late therapy may increases the

clinical presentation is minimal. Prior to surgery,

mortality.

60

For all patients start treatment with

appropriate imaging, no per oral (NPO) status and

liposomal amphotericin B, which is effective against

reversal of coagulopathy are important. The algorithm

mucormycosis. After identification of the causative

for surgical management is illustrated in figure (9). 45

fungus, start targeted antifungal therapy (Fig. 8).45

Endoscopic, open, and combined techniques are used

For Aspergillus species, the first-line is

with serial debridement to eradicate infection. The aim

voriconazole

while

isavuconazole

and

second

options

liposomal

include

amphotericin

B.

of operative intervention is to obtain representative
tissue sample for histopathologic analysis, pathogen

Posaconazole is used in resistant or intolerant cases.

identification,

Echinocandins is used only as one of combination or

susceptibility. Also it aims at removing necrotic tissue

rescue therapy.
invasive

61

Combination of antifungal drugs for

Aspergillus

infection

is

not

fungal

cultures

and

antifungal

and opening up any obstruction.45 Infection control

frequently

measures for COVID-19 included the use of powered

considered, but used as salvage therapy or in critical

air purifying respirators and the exclusion of trainees

cases. Monitoring of drugs must be done for azoles.

from OR.39 Consult ophthalmology discipline if the

About 3.2% of Aspergillus isolates are azole-resisant

orbit

62

is

involved.

In

intracranial

involvement,

and Liposomal amphotericin B is recommended. For

neurosurgery should be consulted. Additionally, oral

Mucor, the drug of choice is liposomal amphotericin B.

surgery should be consulted if there is loose dentition.

For

to

A second surgery after 1–2 weeks is important if

Combination of

clinical picture is not getting better. Repeat CT scan if

intolerant

or

refractory

patients

isavuconazole and posaconazole.

63

switch

azole with activity against mucormycosis (posaconazole
or

isavuconazole)

with

amphotericin

Published by Mansoura Medical Journal, 2023
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there is a plan for second surgery.45
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Fig. (9): Algorithm for medical management of AIFS

45

Fig. (10): Algorithm for surgical management in AIFS 45

https://mmj.mans.edu.eg/home/vol51/iss3/2
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immunocompetent patient. Med Mycol,

Conclusion
Covid-19 patients developing pneumonia require
intensive care, and have risk factors that make them
susceptible to get AIFS. Mortality of AIFS is still high
in spite of improvements in medical and surgical
treatment,. Early diagnosis followed by surgical and
medical treatment of AIFS and consideration of
COVID-19 treatment recommendations are essential for

48:406–409.
5- Werthman-Ehrenreich

A.

(2020).

Mucormycosis with orbital compartment
syndrome in a patient with COVID-19.
Am J Emerg Med,42:264.
6- Guo YR, Hong ZS, Yang Y, et al (2020).

of

The origin transmission and clinical

immunosuppression is the most important predictor of

therapies in coronavirus disease 2019

survival. Also encouraging preventive measures like

outbreak update on statistic. Mil Med Res,

antifungal

7(1):1.

bettering

patient

survival.

chemoprophylaxis

Correction

and

environmental

precautions is essential to decrease morbidity and
mortality.

7- Yan R, Zhang Y, Li Y, et al (2020).
Structural basis for the recognition of
SARS-CoV-2 by full-length human ACE2.
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